text:
Ethnic/Racial Variations of Intracerebral Hemorrhage (ERICH) (ERICH)
This study has been completed.
University of Cincinnati
Massachusetts General Hospital
Columbia University
University of Maryland
Georgetown University
Wake Forest University
Emory University
University of Miami
University of Illinois at Chicago
University of Texas, Southwestern Medical Center at Dallas
The University of Texas Health Science Center, Houston
The University of Texas Health Science Center at San Antonio
University of New Mexico
University of Arizona
University of Southern California
St. Luke's-Roosevelt Hospital Center
University of California, San Francisco
Duke University
University of Virginia
National Institute of Neurological Disorders and Stroke (NINDS)
Information provided by (Responsible Party):
Daniel Woo, University of Cincinnati
ClinicalTrials.gov Identifier:
First received: September 14, 2010
Last updated: August 31, 2017
Last verified: August 2017
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
The purpose of this study is to find risk factors for hemorrhagic stroke, specifically intracerebral hemorrhage (ICH), among Caucasians, African Americans, and Hispanics.
|Intracerebral Hemorrhage
|Study Type:
|Study Design:
|Observational Model: Case-Control
Time Perspective: Other
|Official Title:
|Ethnic/Racial Variations of Intracerebral Hemorrhage (ERICH)
Resource links provided by NLM:
Genetics Home Reference related topics: COL4A1-related brain small-vessel disease
MedlinePlus related topics: BleedingU.S. FDA Resources
Further study details as provided by Daniel Woo, University of Cincinnati:
Biospecimen Retention: Samples With DNA
whole blood
|Actual Study Start Date:
|August 1, 2010
|Study Completion Date:
|August 1, 2017
|Primary Completion Date:
|July 31, 2017 (Final data collection date for primary outcome measure)
3000 Cases
3000 Controls
|Ages Eligible for Study:
|18 Years and older (Adult, Senior)
|Sexes Eligible for Study:
|Accepts Healthy Volunteers:
|Sampling Method:
|Non-Probability Sample
Study Population
Our purpose is to enroll 1000 cases of ICH among whites, 1000 cases of ICH among blacks, and 1000 cases of ICH among Hispanics.
3000 controls matched to cases by race/ethnicity, age (+/- 5 years), gender, and geographic location.
Inclusion Criteria:
All cases must meet the following eligibility criteria:
- Age 18 years or greater, fulfillment of the criteria for intracerebral hemorrhage
- Resident for at least 6 months within 50 miles of the recruiting center
- No evidence of trauma, vascular malformation or aneurysm, or brain tumor as a cause of the hemorrhage
- Ability of the patient or legal representative to provide informed consent
Exclusion Criteria:
Exclusion Criteria:
- Malignancies leading to coagulopathy
- Hemorrhagic transformation of ischemic infarct
- Hemorrhage secondary to dural venous sinus thrombosis
Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01202864
Please refer to this study by its ClinicalTrials.gov identifier: NCT01202864
|United States, Arizona
|University of Arizona
|Tucson, Arizona, United States, 85724
|United States, California
|University of Southern California
|Los Angeles, California, United States, 90033
|United States, District of Columbia
|Georgetown University
|Washington, D.C., District of Columbia, United States, 20007
|United States, Florida
|University of Miami - Biorepository
|Miami, Florida, United States, 33136
|University of Miami
|Miami, Florida, United States, 33136
|United States, Georgia
|Emory University
|Atlanta, Georgia, United States, 30303
|United States, Illinois
|University of Illinois
|Chicago, Illinois, United States, 60612
|United States, Maryland
|University of Maryland
|Baltimore, Maryland, United States, 21201
|United States, Massachusetts
|Massachusetts General Hospital
|Boston, Massachusetts, United States, 02114
|United States, New Mexico
|University of New Mexico
|Albuquerque, New Mexico, United States, 87131
|United States, New York
|Columbia University
|New York, New York, United States, 10032
|United States, North Carolina
|Wake Forest University
|Winston-Salem, North Carolina, United States, 27157
|United States, Texas
|University of Texas Southwestern Medical Center at Dallas
|Dallas, Texas, United States, 75390
|University of Texas Medical School at Houston
|Houston, Texas, United States, 77030
|University of Texas Health Science Center at San Antonio
|San Antonio, Texas, United States, 78229
Sponsors and Collaborators
University of Cincinnati
Massachusetts General Hospital
Columbia University
University of Maryland
Georgetown University
Wake Forest University
Emory University
University of Miami
University of Illinois at Chicago
University of Texas, Southwestern Medical Center at Dallas
The University of Texas Health Science Center, Houston
The University of Texas Health Science Center at San Antonio
University of New Mexico
University of Arizona
University of Southern California
St. Luke's-Roosevelt Hospital Center
University of California, San Francisco
Duke University
University of Virginia
National Institute of Neurological Disorders and Stroke (NINDS)
|Principal Investigator:
|Daniel Woo, MD, MS
|University of Cincinnati
|Principal Investigator:
|Matthew Flaherty, MD
|University of Cincinnati
More Information
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Keywords provided by Daniel Woo, University of Cincinnati:
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on September 21, 2017
Taylor TN, Davis PH, Torner JC, Holmes J, Meyer JW, Jacobson MF. Lifetime cost of stroke in the United States. Stroke. 1996 Sep;27(9):1459-66. Review.
Woo D, Sauerbeck LR, Kissela BM, Khoury JC, Szaflarski JP, Gebel J, Shukla R, Pancioli AM, Jauch EC, Menon AG, Deka R, Carrozzella JA, Moomaw CJ, Fontaine RN, Broderick JP. Genetic and environmental risk factors for intracerebral hemorrhage: preliminary results of a population-based study. Stroke. 2002 May;33(5):1190-5.
Kissela B, Schneider A, Kleindorfer D, Khoury J, Miller R, Alwell K, Woo D, Szaflarski J, Gebel J, Moomaw C, Pancioli A, Jauch E, Shukla R, Broderick J. Stroke in a biracial population: the excess burden of stroke among blacks. Stroke. 2004 Feb;35(2):426-31.
Hardie K, Hankey GJ, Jamrozik K, Broadhurst RJ, Anderson C. Ten-year survival after first-ever stroke in the perth community stroke study. Stroke. 2003 Aug;34(8):1842-6. Epub 2003 Jul 3.
Broderick JP, Phillips SJ, Whisnant JP, O'Fallon WM, Bergstralh EJ. Incidence rates of stroke in the eighties: the end of the decline in stroke? Stroke. 1989 May;20(5):577-82.
Broderick JP, Brott T, Tomsick T, Miller R, Huster G. Intracerebral hemorrhage more than twice as common as subarachnoid hemorrhage. J Neurosurg. 1993 Feb;78(2):188-91.
Barber M, Stott DJ. Validity of the Telephone Interview for Cognitive Status (TICS) in post-stroke subjects. Int J Geriatr Psychiatry. 2004 Jan;19(1):75-9.
de Jager CA, Budge MM, Clarke R. Utility of TICS-M for the assessment of cognitive function in older adults. Int J Geriatr Psychiatry. 2003 Apr;18(4):318-24.
RANKIN J. Cerebral vascular accidents in patients over the age of 60. II. Prognosis. Scott Med J. 1957 May;2(5):200-15.
Flibotte JJ, Hagan N, O'Donnell J, Greenberg SM, Rosand J. Warfarin, hematoma expansion, and outcome of intracerebral hemorrhage. Neurology. 2004 Sep 28;63(6):1059-64.
Goldstein JN, Fazen LE, Snider R, Schwab K, Greenberg SM, Smith EE, Lev MH, Rosand J. Contrast extravasation on CT angiography predicts hematoma expansion in intracerebral hemorrhage. Neurology. 2007 Mar 20;68(12):889-94.
Kumar MA, Rost NS, Snider RW, Chanderraj R, Greenberg SM, Smith EE, Rosand J. Anemia and hematoma volume in acute intracerebral hemorrhage. Crit Care Med. 2009 Apr;37(4):1442-7. doi: 10.1097/CCM.0b013e31819ced3a.
Brott T, Broderick J, Kothari R, Barsan W, Tomsick T, Sauerbeck L, Spilker J, Duldner J, Khoury J. Early hemorrhage growth in patients with intracerebral hemorrhage. Stroke. 1997 Jan;28(1):1-5.
Davis SM, Broderick J, Hennerici M, Brun NC, Diringer MN, Mayer SA, Begtrup K, Steiner T; Recombinant Activated Factor VII Intracerebral Hemorrhage Trial Investigators. Hematoma growth is a determinant of mortality and poor outcome after intracerebral hemorrhage. Neurology. 2006 Apr 25;66(8):1175-81.
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
|Responsible Party:
|Daniel Woo, Professor, University of Cincinnati
|ClinicalTrials.gov Identifier:
|NCT01202864 History of Changes
|Other Study ID Numbers:
R01NS069763-01 ( Other Grant/Funding Number: NINDS )
|Study First Received:
|September 14, 2010
|Last Updated:
|August 31, 2017
Keywords provided by Daniel Woo, University of Cincinnati:
Intracerebral Hemorrhage
Cerebrovascular accident
Additional relevant MeSH terms:
Cerebral Hemorrhage
Pathologic Processes
Intracranial Hemorrhages
Cerebrovascular Disorders
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Vascular Diseases
Cardiovascular Diseases
ClinicalTrials.gov processed this record on September 21, 2017


text:
Today's MLB starting lineups: April 7
Below are the starting lineups that have been made public today by Major League Baseball's clubs.
A lineup is not official until it is handed to the umpire.
Additional lineups will be added as they become available:
Baltimore Orioles vs New York Yankees, 1:05 P.M. EST
|Baltimore Orioles Lineup
|New York Yankees Lineup
Los Angeles Angels vs Houston Astros, 2:10 P.M. EST
|Los Angeles Angels Lineup
|Houston Astros Lineup
Oakland Athletics vs Minnesota Twins, 4:10 P.M. EST
|Oakland Athletics Lineup
|Minnesota Twins Lineup
Cincinnati Reds vs St. Louis Cardinals, 4:15 P.M. EST
|Cincinnati Reds Lineup
|St. Louis Cardinals Lineup
San Diego Padres vs Cleveland Indians, 7:05 P.M. EST
|San Diego Padres Lineup
|Cleveland Indians Lineup
Texas Rangers vs Boston Red Sox, 7:10 P.M. EST
|Texas Rangers Lineup
|Boston Red Sox Lineup
Tampa Bay Rays vs Kansas City Royals, 8:10 P.M. EST
|Tampa Bay Rays Lineup
|Kansas City Royals Lineup
Chicago White Sox vs Colorado Rockies, 8:40 P.M. EST
|Chicago White Sox Lineup
|Colorado Rockies Lineup

subset: commoncrawl


text: OverviewBack to top MHP - Up Your Mass Fudge Brownie - 4.7 lbs. Item# :52810UPC# :666222732503 Brand:MHP Size/Form:4.70 lbs. Ship Weight:5.65 Dosage:4 Scoop(s) Flavor:Fudge Brownie MHP - Up Your Mass Fudge Brownie - 4.7 lbs. (2154 g) MHP Up Your Mass is the most powerful weight gainer ever development. MHP brings the most advanced mass-packing technology to your nutrition program with Up You Mass. The result of over 10 years of research and development, Up Your Mass is so powerful, it can pack 16 lbs. of muscle onto the frame of the hardest gainer in just 5 weeks! The superior quality and quantities of muscle building nutrients in Up Your Mass far outweigh those used in competitor weight gain formulas - you will never find another weight gainer that works as quickly and effectively as Up Your Mass! Triggers Dramatic Gains in Hard, Dense Muscle Mass and Strength Sustained Release Probolic Protein Keeps You 100% Anabolic Optimizes Insulin Response for Maximum Muscle Growth 124,000mg of 18 Highly Anabolic Aminos Per Day! 26g Glutamine, 9g Leucine, 7g Arginine, 23g BCAAs 45/35/20 Macrobolic Nutrition Ratio Creates the Perfect metabolic and Hormonal Environment for Maximum Mass, Strength, Endurance and Recovery Probolic Protein: The most advanced protein matrix ever developed, Probolic protein (Supro soy protein isolate, whey concentrate, casein) feeds your muscles for up to 8 hours. The sustained release profile provides a quick, medium and slow release of muscle building amino acids for both fast and long-term nitrogen retention. Probolic is loaded with mega amounts of Glutamine, Leucine, Branched Chain Amino Acids (BCAAs) and Nitric Oxide boosting Arginine in every serving - all of which are critical for muscle building, strength and recovery from workouts. Mass Load Carbs: The type and quality of carbohydrates used in any weight gainer will determine the type and quality of mass you pack on. Only Up Your Mass contains Mass Load, a unique agglomerate of carbohydrates (barley, oats and oat fiber) that optimizes the anabolic effect of insulin, allowing your body to build dense, high quality muscle mass. The advanced Mass load carb blend also gives you sustained energy, fast glycogen replenishment and stabilized blood sugar levels. Unlike the competition, Up Your Mass is NOT loaded with maltodextrin and sugars (dextrose, sucrose) that can increase fat stores. Lipid Complex: EFAs in Up Your Mass stabilize insulin release and improve nitrogen retention by slowing down carbohydrate and protein digestion. Both are key factors in building muscle quickly. Medium Chain Triglycerides (MCTs) provide an excellent source of energy and help preserve muscle glycogen, while clinically proven CLA is added to further increase lean mass. Up Your Mass Frequently Asked Questions What are the benefits of Up Your MASS?Up Your MASS provides the precise 45/35/20 ratio of macronutrients (carbohydrates, proteins, fats) your body utilizes to create tremendous gains in muscle size and strength, without adding body fat. How does it work?Real Food Ingredients:Glycemix LGI: Carbohydrates are the primary source of energy and are of vital importance to exercise performance. However, high glycemic carbs like sugars (Dextrose, Sucrose) can have a negative impact on performance and body composition. Glycemix LGI includes a unique agglomerate of low glycemic carbohydrates (barley, oats and oat fiber), that provides sustained energy, improved glycogen replenishment and more stable blood sugar levels. Probolic: This dynamic sustained release protein matrix (Supro soy protein isolate, whey concentrate, casein) provides a quick, medium and slow release of amino acids for both fast and long term nitrogen retention. The Probolic protein matrix supplies large amounts of Arginine, Branch Chain Amino Acids (BCAAs) and OVER 5 GRAMS of GLUTAMINE per serving critical for muscle building and recovery. Lipid Complex: Essential Fatty Acids are extremely important nutrients for health and performance. In fact, the right sources of fats may help reduce inflammation, improve hormone functions and provide energy. EFAs slow down the digestion of carbohydrates and proteins, helping to stabilize insulin release and improve nitrogen retention. Medium Chain Triglycerides (MCTs) provide a good source of energy and help preserve muscle glycogen. The Up Your MASS multi-functional Lipid Complex also contains CLA, which has been shown to increase lean mass. Who should take it?Anyone looking to create tremendous gains in muscle size and strength without adding body fat. How should I take it?Mix 1 serving (4 scoops) with 15-18 oz of water 1-3 times a day. The ideal times to take your servings of Up Your Mass are first thing in the morning, an hour before your workout and immediately after your workout. On non-workout days, take Up Your MASS first thing in the morning and 1-2 more times throughout the day. Did you know?MHP's "Every Calorie Counts" credo is being proven by the many pro athletes who use Up Your MASS daily, including 3 of America's Strongest Men: Brian Shaw, Zydrunas Savickas, and Phil Pfister. About Maximum Human Performance (MHP)Like every other workout fanatic out there, you spend countless hours pumping iron to increase strength, add muscle mass and improve performance. Yet you also understand that to succeed in bodybuilding, powerlifting or sports, there is one requirement that is not to be handled haphazardly – supplementation. And when it comes to supplements, one brand stands out as the strongest in the industry: MHP! MHP is the creation of former top-level bodybuilder Gerard Dente. When he was competing, Gerard constantly researched the best training techniques, diet strategies and other performance enhancement methods needed to gain a competitive edge. Yet it was his genius with supplementation that fueled him to be one of the biggest and strongest competitors of his day. In fact, Gerard was using ingredients like high doses of leucine, KIC, tribulus and arginine long before they became popular. He was convinced that athletes deserved better and decided to take some action by founding MHP. Since its inception, MHP's corporate mission has been to develop premier science-based, research-driven sports supplements to help athletes achieve their greatest physical potential. Over the years, MHP has introduced many innovations and breakthroughs in sports nutrition. For instance, MHP was the first company to introduce arginine for nitric oxide production to the bodybuilding world way back in early 1999 (via ADNO – arginine derived nitric oxide), when the company launched the creatine/NO product TRAC. In addition, the patented 12-hour sustained release protein formula in Probolic-SR has been an unmatched industry standard since it was released in 2004. MHP was the first company to introduce the incredible blood-boosting power of EPO in 2008 with Dark Rage. And with new highly advanced GlycoCarn/KNO3 Nitrite-NO Technology now available in NO-BOMB, MHP continues to provide new and exclusive innovations in performance enhancing supplementation. Because of its dedicated research and development, innovative formulations, clinically researched ingredients and cutting edge products, MHP has become the most trusted brand and industry leader among world-class athletes, pro bodybuilders, powerlifters, strongmen and fitness enthusiasts alike. The numerous world records that MHP athletes hold in powerlifting and strongman, plus the many top titles in bodybuilding, fitness and figure, signify how much our supplements are capable of helping athletes achieve. In addition, countless top lifting coaches and trainers also use and recommend MHP products. "All of the elite athletes I work with use nutritional supplements," says Joe Carini, a former powerlifting champion who trains many top NFL stars and strongmen at Carini's House of Iron. "Because of my years of experience as a competitive powerlifter and supplement user, I recommend only MHP products to my athletes."


text:
TMC114-C214: Trial of TMC114 Administered With Low Dose Ritonavir (RTV) in HIV-1 Infected Treatment Experienced Patients
This study has been completed.
Tibotec Pharmaceuticals, Ireland
Information provided by (Responsible Party):
Tibotec Pharmaceuticals, Ireland
ClinicalTrials.gov Identifier:
First received: May 13, 2005
Last updated: July 1, 2015
Last verified: July 2015
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Detailed Description:
Study TMC114-C214 is a randomized, controlled, open-label trial to compare the efficacy, safety and tolerability of TMC114 boosted with low dose ritonavir (RTV) versus Kaletra (LPV)/RTV in lopinavir-naïve treatment-experienced HIV-1 infected patients.
|HIV Infection
|Drug: LPV/rtv Drug: TMC114/rtv
|Phase 3
|Study Type:
|Study Design:
|Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
|Official Title:
|A Randomized, Controlled, Open-label Trial to Compare the Efficacy, Safety and Tolerability of TMC114/RTV Versus LPV/RTV in Treatment-Experienced HIV-1 Infected Patients
Resource links provided by NLM:
MedlinePlus related topics: HIV/AIDS
Drug Information available for: Darunavir Darunavir ethanolateU.S. FDA Resources
Further study details as provided by Tibotec Pharmaceuticals, Ireland:
Primary Outcome Measures:
- Number of Participants with Viral load <400 copies/mL per TLOVR algorithm at Week 48 (Per Protocol Population) [ Time Frame: 48 weeks ]
Secondary Outcome Measures:
- Number of Participants with Adverse Events [ Time Frame: 96 weeks ]
- Number of Participants With Viral load <400 copies/mL per TLOVR Algorithm at Week 96 (Per Protocol Population) [ Time Frame: 96 Weeks ]
|Study Start Date:
|April 2005
|Study Completion Date:
|October 2011
|Primary Completion Date:
|January 2007 (Final data collection date for primary outcome measure)
|Assigned Interventions
Experimental: 002
LPV/rtv One 400mg LPV tablet twice daily with 100mg RTV
Drug: LPV/rtv
One 400mg LPV tablet twice daily with 100mg RTV
Experimental: 001
TMC114/rtv Two 300mg TMC114 tablets twice daily with 100mg RTV
Drug: TMC114/rtv
Two 300mg TMC114 tablets twice daily with 100mg RTV
Detailed Description:
Study TMC114-C214 is a randomized (patients are assigned to different treatment groups based on chance), controlled, open-label trial to compare the efficacy (effectiveness), safety and tolerability of TMC114 boosted with low dose ritonavir (RTV) versus Kaletra (LPV)/RTV in treatment-experienced HIV-1 infected patients. This research study will look at the safety of TMC114 and effectiveness in reducing the amount of HIV(viral load) in the blood. People included in this study will have received either Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) or Protease Inhibitors (PIs) or both. The duration of the study will be approximately 106 weeks, which includes a 4 to 6 week screening period, 96-week treatment period, and 4-week follow-up period. TMC114 300mg are orange tablets where 2 tablets are taken by mouth twice a day with 1 tablet of Ritonavir. Kaletra (LPV/RTV) is either a tablet or capsule taken twice a day. The oral capsule contains 133.3 mg LPV, 33.3 mg RTV and the film-coated tablet is available for oral administration in a strength of 200 mg of lopinavir and 50 mg of ritonavir. Dosing for all medication will occur for 96 weeks and you will be randomly assigned to either TMC114 or Kaletra.
|Ages Eligible for Study:
|18 Years and older (Adult, Senior)
|Sexes Eligible for Study:
|Accepts Healthy Volunteers:
Inclusion Criteria:
- Patient has documented HIV-1 infection
- Treatment with an Antiretroviral regimen (containing at least 2 NRTIs in combination with at least 1 NNRTI and/or 1 PI) for at least 12 weeks
- Plasma HIV-1 RNA >1000 copies/mL
- General medical condition does not interfere with the assessments and the completion of the trial
Exclusion Criteria:
- Patients for whom an investigational Antiretroviral is part of the current regimen, with the following exceptions if applicable (depending on local regulatory approval)
- tenofovir, emtricitabine, atazanavir, fosamprenavir
- Previous or current use of lopinavir, enfuvirtide (T-20), tipranavir and TMC114
- Life expectancy of less than 6 months
- Pregnant or breast-feeding
- Females of childbearing potential not willing to use effective non-hormonal birth control methods or not willing to continue practicing these birth control methods for at least 14 days after the end of the treatment period
- Patients with significantly decreased liver function or decompensation, irrespective of liver enzyme levels
- Participation in other investigational trials without prior approval of the sponsor
Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00110877
Show 107 Study Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00110877
Show 107 Study Locations
Sponsors and Collaborators
Tibotec Pharmaceuticals, Ireland
|Study Director:
|Tibotec Pharmaceuticals Clinical Trial
|Tibotec Pharmaceutical Limited
More Information
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Keywords provided by Tibotec Pharmaceuticals, Ireland:
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on September 25, 2017
Madruga JV, Berger D, McMurchie M, Suter F, Banhegyi D, Ruxrungtham K, Norris D, Lefebvre E, de Béthune MP, Tomaka F, De Pauw M, Vangeneugden T, Spinosa-Guzman S; TITAN study group. Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled phase III trial. Lancet. 2007 Jul 7;370(9581):49-58.
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
|Responsible Party:
|Tibotec Pharmaceuticals, Ireland
|ClinicalTrials.gov Identifier:
|NCT00110877 History of Changes
|Obsolete Identifiers:
|Other Study ID Numbers:
TMC114-C214 ( Other Identifier: Tibotec Pharmaceuticals, Ireland )
|Study First Received:
|May 13, 2005
|Last Updated:
|July 1, 2015
Keywords provided by Tibotec Pharmaceuticals, Ireland:
Human Immunodeficiency Virus
Treatment Experienced
Additional relevant MeSH terms:
HIV Infections
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
Virus Diseases
Sexually Transmitted Diseases, Viral
Sexually Transmitted Diseases
Immunologic Deficiency Syndromes
Immune System Diseases
HIV Protease Inhibitors
Protease Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Anti-HIV Agents
Anti-Retroviral Agents
Antiviral Agents
Anti-Infective Agents
ClinicalTrials.gov processed this record on September 25, 2017


text:
Darwin, 1942: Remembering Australia's 'Pearl Harbor'
By Duncan Kennedy
BBC News, Darwin
Duncan Kennedy meets survivors of the attack on Darwin
It's 70 years since Japanese bombers swooped on Darwin, in northern Australia, sinking Allied ships in the harbour and killing hundreds of people. For years the attack was rarely mentioned, but now the story is finally being told.
If 7 December 1941 is "a date that will live in infamy" for the United States, then 19 February 1942 is surely one that will join it in the annals of shame for Australia.
That was the day, just 10 weeks after the attack on Pearl Harbor, when the same carrier-based Japanese force turned its attention to the small northern town of Darwin, with equally calamitous results.
But the world remembers one and barely recalls the other.


text:
Normal Blood, Bone Marrow and Buccal Mucosa Protocol
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
|Normal Volunteer Controls
|Study Type:
|Study Design:
|Observational Model: Case-Control
Time Perspective: Prospective
|Official Title:
|Normal Blood, Bone Marrow and Buccal Mucosa Protocol
- To provide an Institutional Review Board (IRB)-approved mechanism for the collection of peripheral blood, skin, bone marrow and/or buccal mucosa samples from healthy volunteer donors for use in in vitro studies. [ Time Frame: Throughout study, as normal controls are needed. ]
|Estimated Enrollment:
|Study Start Date:
|December 8, 2008
|Ages Eligible for Study:
|18 Years to 65 Years (Adult)
|Sexes Eligible for Study:
|Accepts Healthy Volunteers:
Ability to sign informed consent.
Healthy male or female between 18-65 years of age.
Willing to have samples stored for future research.
History of an immune deficiency, such as HIV infection or cancer.
History of chronic hepatitis B and/or C infection.
History of chronic anemia.
A known clotting disorder or taking medications that interfere with blood clotting, such as: aspirin, heparin, or Coumadin*
Current pregnancy.
Have taken an investigational drug in the last 6 months that may affect the normal process of blood cells.
Any condition that in the view of the principal investigator (PI) would make the subject unsuitable for enrollment in this study.
* Coumadin and/or heparin treatment will not be stopped so that a subject can participate in this protocol. If Coumadin or heparin was recently discontinued, a subject can be enrolled, but no bone marrow procedures will be performed until the PT and the PTT are within normal range. For other agents that interfere with blood clotting without prolonging the PT, a 7-day washout period will be required before bone marrow sampling.
(Procedure) EXCLUSION CRITERIA
Hemoglobin less than the NIH Clinical Center CRIS normal range.
Platelets less than 100,000/mm(3).
PT or PTT greater than the NIH Clinical Center CRIS normal range
Positive b-HCG.
EKG changes suggestive of cardiovascular disease.
Unable or unwilling to have bone marrow biopsy performed without use of conscious sedation, and use of only local anesthetic during procedure
Any other lab value which may put the subject at risk during the procedure.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00806364
|Contact: Robin R. Eisch, R.N.
|(301) 443-1720
|Contact: Hirsh D Komarow, M.D.
|(301) 594-2197
|United States, Maryland
|National Institutes of Health Clinical Center, 9000 Rockville Pike
|Bethesda, Maryland, United States, 20892
|Contact: For more information at the NIH Clinical Center contact Patient Recruitment and Public Liaison Office (PRPL) 800-411-1222 ext TTY8664111010 firstname.lastname@example.com
|Principal Investigator:
|Hirsh D Komarow, M.D.
|National Institute of Allergy and Infectious Diseases (NIAID)
Additional Information:
|Responsible Party:
|National Institute of Allergy and Infectious Diseases (NIAID)
|ClinicalTrials.gov Identifier:
|NCT00806364 History of Changes
|Other Study ID Numbers:
|Study First Received:
|December 9, 2008
|Last Updated:
|July 12, 2017
Keywords provided by National Institutes of Health Clinical Center (CC) ( National Institute of Allergy and Infectious Diseases (NIAID) ):
Healthy Volunteers
Bone Marrow
Buccal Mucosa
Healthy Volunteer
ClinicalTrials.gov processed this record on September 21, 2017


text:
However, Kristina Kaufmann, a long-time Army wife, knows of three other Army wives, all friends, who took their lives in recent years.
One was Faye Vick, described by Kaufmann as "the perfect picture of an Army wife — pretty, nice, always with a smile." Vick and her family lived around the corner from Kaufmann and near Fort Bragg, N.C. In 2006, when Kaufmann's husband was in Afghanistan and Vick's husband was deployed overseas, the 39-year-old mother placed herself, her infant and her 2-year-old son in a car inside a closed garage and started the engine, asphyxiating all three with carbon monoxide, according to Kaufmann and to local news reports at the time.
"And I know of too many others through the grapevine," said Kaufmann, executive director of Code of Support, an Alexandria, Va.-based nonprofit that seeks to bridge the gap between civilians and military America.
"When you know that you are the anchor — and if you go down, the family's going down — the problem is that you can only do that for so long," said Kaufmann.


text:
Patrick Roberts
November 7, 2007
Patrick Lee Roberts died Nov. 1, 2007, in Sacramento. He was 63.
Memorial services will be held at 2 p.m., Friday, Nov. 9, at Hooper and Weaver Mortuary in Nevada City. Pastor Andy Owens will officiate. A reception will follow.
Mr. Roberts was born May 8, 1944, in Grass Valley to Ernest F. and Mary Louise (Cameron) Roberts. He graduated from Nevada Union High School in 1963 and was a truck driver and a lumber mill sawyer at Bohemia Lumber Mill.
He enjoyed sand-rail trips to Sand Mountain, Nev.' traveling to Hawaii; music; dancing; great food and family get-togethers.
Mr. Roberts is survived by his wife, Karen L. Roberts of Sacramento; sons Jonathan and David Roberts of Grass Valley; daughter Susan Kurvin of Rogers, Ark.; and five grandchildren.
He was preceded in death by his parents, Mary Louise and Ernest F. Roberts.
Recommended Stories For You
Arrangements are under the direction of Hooper and Weaver Mortuary, Nevada City.


text:
Tiagabine is used in combination with other medications to treat partial seizures (a type of epilepsy). Tiagabine is in a class of medications called anticonvulsants. It is not known exactly how tiagabine works, but it increases the amount of natural chemicals in the brain that prevent seizure activity.
Tiagabine comes as a tablet to take by mouth. It usually is taken with food two to four times a day. However, for the first week of treatment you will only take tiagabine once a day. Your doctor will slowly increase your dose (not more often than once each week) until you reach the dose of tiagabine you are to take regularly. To help you remember to take tiagabine, take it around the same time(s) every day. Follow the directions on your prescription label carefully, and ask your doctor or pharmacist to explain any part you do not understand. Take tiagabine exactly as directed. Do not take more or less of it or take it more often than prescribed by your doctor.
Continue to take tiagabine even if you feel well. Do not stop taking tiagabine without talking to your doctor, even if you experience side effects such as unusual changes in behavior or mood. Abruptly stopping this medication can cause seizures. Your doctor will probably decrease your dose gradually.
Your doctor or pharmacist will give you the manufacturer's patient information sheet (Medication Guide) when you begin treatment with tiagabine and each time you refill your prescription. Read the information carefully and ask your doctor or pharmacist if you have any questions. You can also visit the Food and Drug Administration (FDA) website ( Web Site) or the manufacturer's website to obtain the Medication Guide.
Tiagabine should not be prescribed for other uses. Ask your doctor or pharmacist for more information.
Before taking tiagabine,
Talk to your doctor about drinking grapefruit juice while taking this medication.
Take the missed dose as soon as you remember it. However, if it is almost time for the next dose, skip the missed dose and continue your regular dosing schedule. Do not take a double dose to make up for a missed one. If you have missed more than one dose, call your doctor for instructions about re-starting your medication.
Tiagabine may cause side effects. Tell your doctor if any of these symptoms are severe or do not go away:
Some side effects can be serious. The following symptoms are uncommon, but if you experience any of them, call your doctor immediately:
If you experience a serious side effect, you or your doctor may send a report to the Food and Drug Administration's (FDA) MedWatch Adverse Event Reporting program online [at Web Site] or by phone [1-800-332-1088].
Keep this medication in the container it came in, tightly closed, and out of reach of children. Store it at room temperature and away from excess heat and moisture (not in the bathroom).Throw away any medication that is outdated or no longer needed. Talk to your pharmacist about the proper disposal of your medication.
In case of overdose, call your local poison control center at 1-800-222-1222. If the victim has collapsed or is not breathing, call local emergency services at 911.
Symptoms of overdose may include:
Keep all appointments with your doctor and the laboratory.
Do not let anyone else take your medication. Ask your pharmacist any questions you have about refilling your prescription.
It is important for you to keep a written list of all of the prescription and nonprescription (over-the-counter) medicines you are taking, as well as any products such as vitamins, minerals, or other dietary supplements. You should bring this list with you each time you visit a doctor or if you are admitted to a hospital. It is also important information to carry with you in case of emergencies.
AHFS® Consumer Medication Information. © Copyright, The American Society of Health-System Pharmacists, Inc., 7272 Wisconsin Avenue, Bethesda, Maryland. All Rights Reserved. Duplication for commercial use must be authorized by ASHP.
Selected Revisions: September 1, 2009.


text:
Sometimes things seem to change however often they are just the same. I absolutely adore my Sequential Circuits TOM and indeed also my Roland TR-8. Check out the interesting video above showing TOMs glitch mode vs one of the TR-8's Scatter modes.
"I drive Glitch Sound in Sequential TOM, I compared it with Scatter of Roland TR-8." – Yokushe
For more info: vintagesynth.com/sci/tom


text:
Canada Approves Both Cnooc-Nexen, Petronas-Progress Deals
Canadian Prime Minister Stephen Harper approved Cnooc Ltd. (883)'s $15.1 billion takeover of Nexen Inc. (NXY) and Petroliam Nasional Bhd.'s C$5.2 billion ($5.2 billion) takeover of Progress Energy Resources Corp. (PRQ)
The deal by Beijing-based Cnooc is the largest ever takeover by a Chinese company, according to data compiled by Bloomberg. It gives the state-owned company a stake in Canada's largest oil-sands project and the biggest position in the Buzzard oil field in the U.K. North Sea.
China is securing global reserves to feed demand in the world's second-largest economy, which accounted for half of the world's oil consumption growth in 2011, according to the U.S. Energy Information Administration. Harper, who has touted Canada as an emerging "energy superpower," has called it a national priority to diversify energy exports, sending less to the U.S. and more to Asia.
"It's important to have clarity on this, not just for Canada's foreign relations with certain super-power nations but also to ensure timely development of these very important resources," said Robert G. Gill, portfolio manager at Toronto- based Aston Hill Financial, which has more than C$6 billion assets under management.
Tested Ability
The two bids tested Harper's ability to balance the need to bolster economic relations with Asian economies without letting them gain too much influence over the world's third-largest pool of oil reserves.
"I express my appreciation for Canada's welcome of our investment," Wang Yilin, chairman of Cnooc, said today in a statement. The deal "recognizes the long-term economic benefits for Calgary, for Alberta and for Canada. Our company will also benefit by adding Nexen's impressive assets and outstanding employees to our worldwide operations."
While allowing the takeovers, Harper said Canada won't approve state-owned companies taking controlling interests in any more oil-sands projects, except in "exceptional circumstances."
Difficult Decisions
"These were difficult decisions" that reflect "the broad views of Canadians," Harper told reporters. Canada relies on exports for one-third of economic output and counts on energy products for almost one-quarter of those shipments.
"From a perspective of industry this is the perfect solution," said John Stephenson, who helps manage C$2.7 billion at First Asset Management Inc. in a phone interview from Toronto. "You get the benefit of patient capital servicing value for investors and you don't give up control, which is really the issue most Canadians feel passionately about."
Canada is effectively "grand-fathering the Cnooc and Petronas deals," Stephen Wortley, a partner at McMillan LLP and chairman of the Canadian law firm's Hong Kong office, said in an e-mail. "At the same time the government is signaling that tougher standards will be forthcoming especially in the oil sands, where there is a concern about the potential for concentration" of foreign state-owned companies, he said.
Shares Rally
Shares of Calgary-based Nexen rallied 15 percent to $26.94 as of 6:19 p.m. New York time in trading after U.S. exchanges closed, 2 percent below Cnooc's $27.50 offer. The Canadian dollar strengthened, rising 0.3 percent to 98.84 cents per U.S. dollar as the announcements were made.
The Cnooc-Nexen transaction is the biggest in Canada since Calgary-based Suncor Energy Inc. (SU) bought Petro-Canada in August 2009 for about $18 billion. Through its C$2.1 billion acquisition of Opti Canada Ltd. last year, Cnooc already owns 35 percent of the Long Lake oil-sands project operated by Nexen. It would gain Nexen's 20 percent interest in the Usan offshore Nigerian project operated by a unit of Total SA.
'Significant Benefits'
"This is an important milestone in the process and confirms our belief that this transaction provides a number of significant benefits to Canada and to Nexen," Kevin Reinhart, Nexen's interim president and CEO, said in statement. "We remain focused on working with Cnooc to bring this transaction to a close."
Progress shares (NXY), which surged 74 percent on the day the first bid by Petronas was announced June 28, closed at C$19.35 in Toronto. Petronas offered C$22 a share.
"We're obviously quite pleased with the decision," said Michael Culbert, chief executive officer of Calgary-based Progress, by phone. "We know that this has been a difficult decision to make and we don't take that lightly."
Azman Ibrahim, a spokesman for Petronas in Kuala Lumpur, couldn't immediately comment when phoned by Bloomberg News today.
LNG Terminal
The acquisition of Progress by Petronas gives the Malaysian state-owned company gas reserves to build a liquefied natural gas export facility along the British Columbia coast at a cost of C$9 billion to C$11 billion, the companies said this week.
Petronas has the world's largest LNG-producing site in Sarawak, Malaysia, according to its website, and also operates the world's largest LNG carrier fleet.
The Canadian decisions came on the same day Glencore International Plc (GLEN)'s C$6.1 billion takeover of Viterra Inc. (VT), Canada's largest grain handler, received Chinese regulatory approval.
Investment by Chinese state-owned companies in Canada's energy industry has become a contentious issue, and the deals represent the end of a trend of state-owned companies buying Canadian oil-sands firms, not the beginning, Harper said.
Still, the decision "will serve as a catalyst for inbound investment by Chinese private concerns into the Canadian market place," said Wortley at McMillan. "We are already seeing significant activity in this area."
'Irresponsible, Farce'
Fifty-eight percent of Canadians wanted the government to block the Nexen takeover, according to an online poll of 1,000 people taken Oct. 10 to Oct. 11 by Angus Reid Public Opinion.
The opposition New Democratic Party called the Cnooc approval "irresponsible" because most Canadians oppose the purchase. "This is a farce," Peter Julian, the NDP's spokesman on natural resources, said in a statement. "While Conservatives admit that under the new rules this transaction is not a net benefit to Canadians, they have approved it anyway."
Natural Resources Minister Joe Oliver has said the country's biggest resource projects will require nearly C$650 billion of investment to develop over the next decade.
Harper said Canada will raise the threshold for foreign- takeover reviews by private investors to C$1 billion in enterprise value as earlier planned, while the existing threshold of C$330 million in asset value will continue to apply to state-owned enterprises. Industry Minister Christian Paradis will also have the ability to extend the review period to take national security analyses into account, Harper said.
Gulf Assets
Foreign state-owned businesses will still be welcome to acquire minority stakes and enter into joint ventures with Canadian businesses, Harper said.
Cnooc, which said it received approval from the European Union today on the deal, has not said whether U.S. authorities have approved its takeover of Nexen's assets in the U.S. Gulf of Mexico, where the Calgary company gets eight percent of its production.
Natalie Earnest, a spokeswoman at the U.S. Department of the Treasury that oversees the Committee on Foreign Investment in the U.S., declined to comment in an e-mail, citing confidentiality rules.
Scrutiny of foreign takeovers has stymied deals in North America before. Cnooc was forced in 2005 to abandon a $19 billion hostile bid for El Segundo, California-based Unocal after U.S. lawmakers proposed legislation to block it.
Listing in Toronto
Cnooc had already made several commitments to Canada to win support for the Nexen sale. These include listing its shares on the Toronto Stock Exchange (SPTSX), establishing Calgary as its base for North and Central America and maintaining Nexen's employment levels and capital spending program.
Cnooc accepted management and employment conditions set by the Canadian government, two people familiar with the matter said Nov. 20.
The deal will also benefit Cnooc's domestic operations, allowing it to "transfer some of the shale gas and deep water expertise back into China," Gordon Kwan, head of energy research at Mirae Asset Securities HK Ltd., said by telephone. "Nexen's Gulf of Mexico assets will help Cnooc further develop South China Sea reserves."
Approval of the Petronas bid came after Paradis blocked the bid on Oct. 19 and gave the companies 30 days to make additional concessions.
To contact the reporters on this story: Andrew Mayeda in Ottawa at firstname.lastname@example.com; Greg Quinn in Ottawa at email@example.com
To contact the editor responsible for this story: David Scanlan at firstname.lastname@example.com


text:
OK, here's the deal. Basically, Trombone Shorty owns the Monterey Jazz Festival. Lock, stock and barrel.
From now on he can pretty much do what he wants when he wants.
After his smashing breakout debut performance two years ago on the Garden Stage, and his triumphant return Saturday afternoon, this time in the main arena, Shorty, given name Troy Andrews, can call his own shots at this festival. He could probably come back every year and nobody would bat an eyelash.
Shorty — can I call him that? — grabbed the audience by the, um, collar from the get-go and didn't relinquish control until he was well off the stage after the finale, a rousing version of Ray Charles' classic "I Got a Woman."
He pulled out all the stops and dug deep into his trick bag for his 90-minute set, playing an extended solo on his trumpet that seemed to go on forever using circular breathing technique (either that or he has a gigantic set of lungs), doing a call-and-response on the classic "St. James Infirmary," ("Hi-di-hi-di-ho!") — even switching instruments with other band members so he ended up on bass, the bass player playing trumpet, the guitarist playing sax and so forth. It was gimmicky, but it worked. The capacity audience couldn't get enough.
By the time he was finished the audience didn't know which way was up, except for the screaming F-16 Thunderbirds that buzzed the arena a few times.
"Get on up!" "Get down!" "Put 'em up!" "Get off your seats!" "Get funky!" "Can you feel it Monterey? Can you feel it?"
Well, if you couldn't, you were either a.) Not in the arena, or b.) Seriously in need of professional help.
And making a bid to be this year's Trombone Shorty was pedal steel guitar player Robert Randolph, who made thousands of new fans at two shows in the arena and Garden Stage.
Although not for all tastes, Randolph's music is filled with a lot of rock sound and fury, and he nonetheless set the stage for Shorty's show with a powerful set of gospel-drenched funk and rock in the arena.
And then once he got on the smaller, more intimate Garden Stage, he pulled a Trombone Shorty, drawing a huge, standing-room-only crowd that he had dancing and clapping along by the end of his set.
At one point he even invited women to come up on stage and dance to the Slim Harpo classic "Hip Shake." When about a half-dozen jumped up, he half-mockingly said, "That's it? I need 20 more!" And he got it, to the delight of the crowd and the women on stage, who looked like they were in a free-for-all dance revue. I believe that was a festival first. Well, I've never witnessed anything like it and a longtime festival photographer just laughed and said that was a first time for him, too.
Randolph and his tight funky band ripped into a furious funk workout, "Work It to the Bone," to end their festival debut, one that will rank along with Trombone Shorty's two years ago as one of the most memorable in festival history.
Even the other bands Saturday afternoon didn't back down from the formidable challenge posed by Shorty and Randolph — the Blues Broads delivering a crowd-pleasing set of R&B, blues and gospel, and Austin's Mingo Fishtrap offering some straight-up '70s-style funk and soul. That wasn't the only music of the afternoon by any means, but it sure made quite an impression on festival-goers.
Sunday afternoon at the jazz festival is probably the most laid back, with mostly student bands taking up the bulk of the shows, and the centerpiece being the Next Generation Jazz Orchestra performing in the main arena with Artist in Residence, trumpeter Ambrose Akinmusire as guest artist.
The Next Gen doesn't draw a huge crowd, but it's often the best music of the afternoon, and jazz fans, especially those of big band music, would be foolish to ignore it.
The big name of the afternoon is bassist/vocalist and Grammy Award-winner Esperanza Spalding, making her second appearance at the festival.
Sunday is also Family Day at the festival, with a number of activities for kids and performances by the Banana Slug String Band out of Santa Cruz.
The evening shows are another story, packed with a wealth of name acts, including the always popular Hammond B-3 Blowout, the Kyle Eastwood Band, Jack DeJohnette-Bill Frisell Duo, the all-star Ninety Miles Band, Pat Metheny Unity Band, and Monterey Jazz Festival Tour Band, which features veteran jazz stars vocalist Dee Dee Bridgewater, bassist Christian McBride, Ambrose Akinmusire, saxophonist Chris Potter, pianist Benny Green and drummer Lewis Nash.
The final act of the weekend is expected to be the Chester Thompson Quartet, led by the former Santana and Tower of Power keyboardist Thompson and San Jose blues guitarist Chris Cain, part of the three-band Hammond B-3 Blowout that also includes the John Abercrombie Trio and the Larry Goldings Trio.
Mac McDonald can be reached at 646-4351.


text:
Well here's a concept worth mentioning: a drum loop blog. There's not too much to say here other than Boston, Massachusetts resident Ryan Gruss posts a drum loop a day for all of us to use and abuse. He's categorizing his loops so this could be a place to go when on a beat hunt.
"Hey Oliver, I just wanted to drop you a note and say hi. recently started a blog of my own. I record and upload new drum loops everyday (almost) for anyone to use. I post a quick audio preview and supply a download link to the original Logic files." – Ryan Gruss
No drummer jokes ok? (NO NO I'm joking… please leave many drummer jokes in the comments!)
Check out the blog and loops here: ryangruss.com
photo credit: johnnyalive


text:
Healthy Origins was founded in 1996 with a mission to provide a healthy value from reliable origins. This Pittsburgh-based manufacturer of nutritional supplements provides top quality products from some of the most reputable suppliers in the world. Their products are manufactured with strict compliance to the FDA guidelines and contain no hidden fillers, binders or coatings. This ensures you are receiving a product with no diminished bioavailability that is made with the highest integrity. So whether you're searching for cardiovascular health or weight loss support or anything in between, Healthy Origins is there to help!
You're now signed up to receive exclusive deals and savings opportunities!
Thank you for your interest and be assured that you will continue to receive our emails at this address.
We are having trouble processing your request. Our apologies! Please try again later.


text:
Amid a fresh round of reports Friday that a Seattle group was about to buy the Kings from the Maloof family, two more deep-pocketed bidders said they were interested in buying the troubled franchise and keeping it in Sacramento.
Bay Area investor Mark Mastrov, the founder of the 24 Hour Fitness chain, told the Sacramento Bee he has assembled a group to buy the Kings and "work with the city to get an arena deal if possible."
Mastrov was a finalist two years ago in the bidding for the Warriors.
Also expressing interest in playing some role was Dale Carlsen of Sleep Train Mattress Centers Inc., whose company is the naming sponsor of the Kings' arena.
Carlsen said he has talked with other potential investors as well as Mayor Kevin Johnson, who has vowed to present a credible hometown offer that could compete against the Seattle group.
A new report Friday by a Comcast Sports analyst said the Maloofs had a handshake agreement to sell the team for $525 million to hedge-fund manager Chris Hansen and Microsoft executive Steve Ballmer.
Grizzlies 101, Spurs 98: Rudy Gay hit a pull-up jumper from 14 feet with 27.8 seconds left, and host Memphis held off San Antonio in overtime.
Thunder 116, Lakers 101: Kevin Durant scored 42 points, Russell Westbrook had 27 points and 10 assists, and Oklahoma City easily sent Los Angeles to its sixth straight loss.
Wizards: The team says point guard John Wall has received "full medical clearance" and will make his season debut Saturday against Atlanta.
The Associated Press contributed to this report.


text:
7654321 See what's next 7654321
More On Investments:
Bankrate wants to hear from you and encourages thoughtful and constructive comments. We ask that you stay focused on the story topic, respect other people's opinions, and avoid profanity, offensive statements, illegal contents and advertisement posts. Comments are not reviewed before they are posted. Bankrate reserves the right (but is not obligated) to edit or delete your comments. Please avoid posting private or confidential information, and also keep in mind that anything you post may be disclosed, published, transmitted or reused. We do not permit the inclusion of hyperlinks in comments and may remove any comment that includes a hyperlink.
By submitting a post, you agree to be bound by Bankrate's terms of use. Please refer to Bankrate's privacy policy for more information regarding Bankrate's privacy practices.
Dear Dr. Don, The youngest of 6 children, I am 48 years old. My father joined the Navy at 22. In Italy, he met his bride and my mother, and returned to the U.S. to raise our family. In 1959, he bought a trust certificate... Read more


text:
RIO DE JANEIRO--Brazilian oil startup HRT Participacoes em Petroleo SA (HRTPY, HRTP3.BR) said late Thursday that Namibia's Mines and Energy Ministry approved the sale of a stake in three offshore blocks to Portugal's Galp Energia (GALP.LB).
In the deal, first announced in November, the two companies said that Galp had acquired a 14% stake in the three exploration blocks in return for covering a portion of drilling costs.
The deal helps clear the way for HRT to start drilling in the highly prospective region off Namibia's coast, which geologists believe could hold an area similar to Brazil's subsalt because the two areas were connected millions of years ago. Billions of barrels of crude oil were discovered under a thick layer of salt in the Atlantic Ocean off Brazil.
"We can confirm we will commence operations in [first-quarter 2013] for our exploratory campaign in Namibia," HRT Chief Executive Marcio Rocha Mello said in a statement. Earlier this month, HRT recently received the drilling rig that will be used to drill exploration wells in the offshore blocks.
Oil-industry consultants DeGolyer and MacNaughton pegged average prospective resources for HRT's offshore acreage in Namibia at 7.4 billion barrels of oil equivalent. Average prospective resources are a preliminary measure used by the industry to indicate oil volumes that could be recovered from undiscovered deposits.
HRT holds operating stakes in 10 blocks and minority shares in two others in the Walvis, Orange and Namibe basins.
Copyright (c) 2012 Dow Jones & Company, Inc.
Click on the button below to add a comment.
Generated by readers, the comments included herein do not reflect the views and opinions of Rigzone. All comments are subject to editorial review. Off-topic, inappropriate or insulting comments will be removed.
Related Companies
More from this Author
Most Popular Articles
Regional News
From the Career Center
Jobs that may interest you


text:
A Michigan House panel is hearing testimony on a proposal that would end Blue Cross Blue Shield of Michigan's tax-exempt status and transform the giant health insurer from a charitable trust to a customer-owned nonprofit.
The House Insurance Committee on Tuesday was listening to backers and critics of the proposed overhaul of the state's largest insurer that has already passed the state Senate.
Consumer advocates such as Don Hazaert, executive director of Michigan Consumers for Healthcare, said deregulating the Blues from its monopoly and nonprofit status will likely lead to higher premiums.
However, supporters said adequate regulations are preserved and the legislation "levels the playing field" for all state insurers.
BCBSM insures 70 percent of Michigan residents, or 4.4 million people, including those with pre-existing conditions. As a nonprofit, it currently pays no state of local income taxes.
Insurance Committee Chairman Pete Lund, a Shelby Township Republican, said Tuesday another hearing is scheduled next week and he wants the measure to get a full House vote by year's end.
The measure being considered would amend state health regulations and the state insurance code.
Don Hazaert, executive director of Michigan Consumers for Healthcare, said deregulating the Blues from its monopoly and nonprofit status will risk higher premiums.
Hazaert said the legislation would allow the Blues to raise rates without prior oversight by state regulators unless the hike was greater than 10 percent under a "file and use" procedure.
"Nothing in this deal benefits Michigan residents," he said in meeting with editors at The Oakland Press.
BCBSM has a market value of between $6.4 billion and $10 billion and Hazaert said "an evaluation" of the company is essential.
The legislation calls for the Blues to pay $83 million a year to a charitable foundation for 18 years or about $1.5 billion, far less than what its value is believed to be, eliminating between $4.5 billion and $8.5 billion in citizen-owned charitable value of the Blues.
If the status of BCBSM is changed, it� requires approval by the Blue Cross' board of directors. Gov. Rick Snyder has said he'd approve the measure if it reaches his desk.
The legislation under consideration is Senate Bills 1293 and 1294.
Contact Jerry Wolffe at 248-745-4612 or firstname.lastname@example.com or follow him on Twitter @JerryWolffe1 or on Facebook. The Associated Press contributed to this report.


text:
This game was classified by the community with the following category scores - Violence=1/3, Sex=0/3, Mature Content=1/3. In this fast action infinite shooter, four turrets seeking thrills encounter a young horde in the desert. After dispatching their infantry, they begin scheming on a crippled old mollusk, reputedly hiding a tidy sum of cash. They become houseguests of the mollusk, not realizing the old mollusk has a few sinister intentions of his own.
Buy Xbox content on Xbox.com. Your Xbox 360 console will automatically download the content next time you turn it on and connect to Xbox Live.Learn More


text:
[Page 279]
Our family home in which I was born and raised stood on Baron Hirsch Street. The synagogue stood at one end of that street, at the corner of Pansak Street, and the Greek Catholic church stood at the other end, at the corner Brzezanska Street. The street was raised, but there was no paved roadway or sidewalk. On rainy days and when the snow was melting, we sank into the mud every time we left our house. During the winter, in the season of ice and snow, the slope served as a sledding area for the children of the city.
There were eleven people in our family, including Grandmother Malka of blessed memory. The atmosphere in the home was tradition, and saturated with popularity. My parents related to the Zionist movement with understanding, and they also did not spare any effort to impart Jewish and general education to us. This helped each of us to find our way in life.
Our home was open to everyone on weekdays, Sabbaths and festivals. My mother of blessed memory would offer assistance to the needy in a discrete fashion. Her personality exemplified the Jewish mother (Yiddishe Mama) in the full sense of the term.
The dear members of my family perished in a tragic manner in the ghetto, like all the people of our city. When I made aliya to the Land in 1939 and bade farewell to my family members, my dear ones said to me: Who knows if we will see each other again alive To my great sorrow, the suspicions were actualized and became the bitter truth. From that time, I bore their last words in my heart, and their memory will not leave me forever.
Baruch (Bunia) Shotten
The Shotten family in 1939
Sitting in the center Avraham Shotten and his wife Rivka.
At the left the eldest daughter Mina and on the right, her husband Gedalya.
Standing from left to right: the eldest son Moshe Yossel and his wife Chaichia,
the daughter Dunchia, the son Baruch (Bunia), the daughter Golda,
the son Bernard (Berchia) and his wife, and the youngest daughter Leah (Leika)
[Page 280]
From the distance of many years, the bright image of our only son Yigal of blessed memory looks upon us.
I remember him from his earliest life, when he was still in his diapers. He was a ruddy, healthy child with beautiful eyes, upon which the azure skies of the homeland peered and imparted their color. From the time he first saw the light of the world, he spread his nest with great love, warmth, and boundless dedication.
The child grew and became a lad head and shoulders above his friends. The three links in our small family became a wonderful chain, in which our son Yigal became the chief link. With the passage of time, true friendship and deep mutual understanding was forged within our small family, forming the unique character of relationships among us.
The lad grew up and became a tall, bright youth, dreaming, visualizing and content with his lot. He had a good heart, feeling the burdens of his fellows and behaving pleasantly to every person. What was most wonderful about him was the wonderful blend of youthful dreams and healthy logic, with a developed sense of justice and correctness. There was always an enthusiastic smile on his face. A sensitive heart hid behind the smile, prepared at all times to help anyone in need of assistance.
Thanks to his clear mind and sharp intellect Yigal succeeded in becoming an excellent student without a great deal of effort. He read a great deal, and was also a good sportsman. Yigal was a member of the scouting organization, and was sent by them to be a counselor for children who were having difficulty with education. Yigal invested a great deal of effort and energy until he succeeded in imparting scouting values to these children, and to make a life of work combined with a life of the spirit dear to them. All of this was done with seriousness and persistence, as was his way with any task that he undertook.
Our son Yigal was blessed with talents. He was talented in handiwork. He wove cloths and created many useful tools for the household. He had unusual artistic talent, to the point where he succeeded in completing his studies in a school of art and sculpting. Nothing was too difficult for him, and it seemed that he had sufficient time for anything that he chose to do.
[Page 281]
His artistic talents were accompanied by deep commitment and dedication to the difficult daily work. We once asked him if he was preparing for a career as an artist, since he devoted so much time and energy to this. His answer was: For me, this is only a hobby. I see my future in medical research, and it is to that that I wish to dedicate my life. Indeed, he read a great deal of medical books, and he devoted most of his free compositions in school to those topics.
Suddenly there was a convention of the scouting movement which was accompanied by a tour throughout the land. He returned from the convention tired, sick and feverish. He went to the hospital, but the source of the disease was unclear. The disease progressed quickly in an unexpected manner until the bitter end.
The last days of our son Yigal are etched in our mind. We will not forget them until our last day. We stood by his bed as evening was falling, before the bitter and despised day. Our son was discussing the convention with us, and he suddenly said, The birds are chirping outside and I am going to die What are you talking about Yigal? You will recover, and you will live. Yes, yes, the penicillin will save me , he added and smiled at us.
The next morning, when you saw us standing at both sides of the bed, you extended your hands as a sign of farewell, looked at us, and two tears rolled down your eyes. We understood this was the end
Our son Yigal was ill for a number of days, and at 6:00 p.m. on the 19th of Tishrei 5607 (1948), he returned his soul to his creator. He was only 17 years old. Our son died in the prime of his life, and we were left bereft and bereaved, having drunk the cup of agony in its fullness.
May his memory be blessed.
Bluma and Menachem Ettinger
The gravestone of Yigal Ettinger
JewishGen, Inc. makes no representations regarding the accuracy of
the translation. The reader may wish to refer to the original material
for verification.
JewishGen is not responsible for inaccuracies or omissions in the original work and cannot rewrite or edit the text to correct inaccuracies and/or omissions.
Our mission is to produce a translation of the original work and we cannot verify the accuracy of statements or alter facts cited.
Podgaytsy, Ukraine Yizkor Book Project JewishGen Home Page
Copyright © 1999-2017 by JewishGen, Inc.
Updated 18 May 2007 by LA


text:
Topic: Devoncat where are you??
Hi everyone,
I haven't "seen" Kris on here for a while. Was just wondering if anyone has talked to her.
cholangiocarcinoma.org :: Cholangiocarcinoma Foundation Discussion Board
a resource for patients, friends, caregivers and loved ones.
You are not logged in. Please login or register.
|La fundación de colangiocarcinoma (CCF) ahora ofrece servicios de traducción en Español.
Por favor publique sus preguntas en Español y un intérprete le va responder.
Join our new Mentoring Program
A new discussion board experience is coming this September!
After 10 years, we're upgrading our discussion board to a new modern system. The new forum will be easier to use, mobile-friendly and loaded with new features! We'll be taking all of the existing posts and users over to the new board, you won't have to do anything. If you have any questions, we've started a thread here to discuss.
Hi everyone,
I haven't "seen" Kris on here for a while. Was just wondering if anyone has talked to her.
I had spoken with Kris about three weeks ago. Her and Hans are contemplating meeting up in Barcelona at the World Congress for GI Cancers. I told Hans today, that Kris is being missed on this board. She is experiencing some side effects from the chemo but, I am sure that we will hear from her, real soon. I made sure to send all our love to her.
Thanks, Marion. Have been missing Kris also. How neat that you are going to meet Kris and Pauline!
Sorry guys, I have been in the hospital for over a week. I got SEVERE diarreah and vomiting which caused a very slipperly slope with dehydration, malnutrition, a 103 fever and alll my body salts and nutrients were out of wack.
Home now. I am tired but fine. Still a little diarreah, but no vomiting and all my nutritional results are fine.
It happened so quickly. Thursday was my last zeloda day and I was looking forward to a wonderful week off. Suprise....not a wonderful week off. I am supposed to go back on another round on tuesday, but we are going to talk to the oncologist about waiting a couple more days.
My best friend from University of South Carolina (GO COCKS!) is coming today for 2 weeeks. She is a ped onc so she knows the score and will be looking out for me.
Thanks for your concern.
Glad to hear you are doing a bit better, but not so happy to hear of the upset. Tired is OK compared with all the rest. Have a great time with your friend the next two weeks. Take care.
Thinking of you,
Did your oncologist think that the zeloda was what caused your problem? Mom had very similar reaction. Her oncologist didn't think that the zeloda was what made her so sick, but when Mom talked to the nurse who called from zeloda she thought that it probably was from the zeloda..... what to do, what to do!
I am so sorry that you have been feeling crummy, but I am really glad to hear from you.
Please take care. Enjoy your friends visit!!!
I think about you a lot and will be praying for you and everyone here. Big hugs.
Kris, Kris, - You're a Gamecock fan? Oh No! Go Tigers (Clemson that is)!
Sorry you were out of whack, but now have fun with your friend!
Glad you are home. Take care and have a nice visit with your friend. Sending good thoughts and prayers your way.
God Bless, Jamie
Nice to see you again. Hope that you're feeling better. Have a ginger ale for me!
The information expressed is not medical advice. The discussion boards are not intended to replace the services of a trained health professional or to be a substitute for the medical advice of physicians or other healthcare providers. Read the full disclaimer.


text:
Moderators: Timko, Fritz, Solty, Booter, Blake_T, Frank Delicious
Frank_Delicious wrote:the Knee High wool socks from Bass Pro Shops are great. I forget the brand but they wick great plus you can pull them up and it helps keeps ticks and poison ivy off you. After the last tourney I was the only guy who didn't get tore up by chiggers and briars b/c of those socks.
grodney (IOWADG.COM) wrote:There are no righty holes, no lefty holes, no hyzer holes, no anhyzer holes. There is only skill and lack of skill.
Tim_the_Enchanter wrote:heh, a tip I heard from a guy I golfed with once, if you want the "cool" socks, like argyle or striped, especially in less than traditional colors, go to the women's section of a Target or something similar. I suppose it takes some comfort with your masculinity to do that, but hey, whatever. Dude had on a pair of light blue and white argyles that I never would have guessed were women's socks until he told me.
jsun3thousand wrote:Disc golfers are holding the sport back.
jnecessary wrote:Just ordered 3 pair of SmartWools on steepandcheap.com. We shall see how they turn out. I've never worn anything other than generic "athletic" socks, so I hope they make it easier playing on long hot days.
Users browsing this forum: No registered users and 1 guest


text:
Our official IRC channel is #vgmdb on irc.psigenix.net
You may use any IRC client such as mIRC to connect. Alternatively you may chat in your browser window using the form below.
If you are unable to run Java applets, please choose CGI:IRC from the dropdown menu. Note that there is a limit to the number of connections allowed for this option.


text:
As it turns out, mom was right when she said that breakfast was the most important meal of the day.
According to the "Ending Childhood Hunger: A Social Impact Analysis" study, kids who eat school breakfasts miss fewer days of schools, do better in math and are more likely to graduate high school.
"This report demonstrates that investing in our children and economic prosperity go hand-in-hand and merit bipartisan support," Billy Shore, founder and CEO of Share Our Strength, said in a news release. "The seemingly simple act of ensuring that children get school breakfast offers the potential for students to experience greater academic achievement, increased job readiness and ultimately more economic prosperity for our nation. Stronger, better nourished kids mean a stronger America."
In particular, students who eat school breakfast
- Score 17.5 percent higher on standardized math tests
- Attend 1.5 more days of schools
- Are 20 percent more likely to graduate from high school
The importance of breakfast was also highlighted this week by USDA Secretary Tom Vilsack as he helped kick off National School Breakfast Week.
"Making sure that children get the best start to their day is part of our commitment to providing all of our children access to safe, nutritious, and well-balanced meals," Vilsack said in a new release. "Eating breakfast helps maintain a healthy weight and gives our youngest generation the greatest chance at success."
As one of the most popular breakfast drinks, milk also plays a vital role in keeping students fit.
In 2009, a study found that teens who consumed the recommended daily serving of dairy had lower body mass index and less body fat than those who ate fewer servings. A study in 2012 found similar results in milk-drinking teenage girls. Another study in 2011 found that milk and other sources of vitamin D play an important role in children's diet after a study links allergy risk to low intake of the vitamin.
"About half the students in the county live around the poverty level. For many, school lunch and breakfast are the main meals of the day," Dr. Sanjay Gupta said in an interview with CNN, available here. "Without milk, local doctors said, kids weren't getting enough vitamin D, vitamin A, calcium, or potassium."


text:
Posted 5 years ago
(304 items)
I went through all of my magazines & tear sheets this week, saw the sun rise 3 times! 1,000's of ads, images etc. This is one of the many ads I am in love with & I finally found a frame it would fit. The image is bright & beautiful with little to no color fade. Nice little write up about celebrating the 4th & listening to the patriotic music Columbia offered. Ive been wanting to post this image for some time now, better late then never.
The other image is from the same magazine & was the illustration to a story, another I'm in love with.
Thanks for looking.


text:
A LONG-AWAITED review of emergency care across Worcestershire has won approval from taken a step closer to completion.
The Worcester Urgent Care Strategy sets out plans for how emergency healthcare and treatment will be dealt with in future years following falling budgets and increased pressure on hospitals and was developed by a number of health bodies in the county.
The strategy took on board recommendations in last year's report into national healthcare by Sir Bruce Keogh and was presented to a meeting of the Worcestershire Acute Hospitals NHS Trust on Wednesday, January 29.
The Trust's chief executive Penny Venables said she was delighted the report - which she said was "even more important" than the currently in-progress review into the three emergency hospitals in Worcestershire - was finally ready after about two years of hard work.
"This is the more fundamental challenge and it has to be successful," she said.
"It is based on care in your own home as much as we can deliver it.
"We can care for frail and elderly people much more do that more successfully if we get them out to their own homes.
"It take so much longer to get the right bed and the right place and elderly people deteriorate in terms of dependency at places like care homes and hospitals."
But she said the plans were "not just about beds".
"The devil's in the details for how we make this happen," she said.
"Its got to be about doing things in a different way."
The report contains a wide range of recommendations aimed at creating closer ties between emergency departments, community hospitals, social care and other elements of healthcare to ensure patients are given the best and most efficient healthcare possible.
A key element of the plans is to ensure patients are not in hospital any longer than they need to be to avoid so-called bed-blocking.
The board's director of strategic development Christine Fearns described it as "a very significant document".
"There are a lot of factors that are important," she said.
"We've got to acknowledge the challenges we face as we try and address these challenges."
But board member Andre Sleigh said it was important as many recommendations were put in place as soon as possible.
"The glacial pace that some things move in the NHS is a real concern," he said.
To view the report visit worcsacute.nhs.uk


text:
If you receive a ticket for a non-criminal moving violation, and
you do not hold a commercial driver license, you may elect to attend
a basic driver improvement course to avoid points on your driving
If you choose to attend a basic driver improvement
course, no points will be charged to your driver record, adjudication
of guilt is withheld, your safe driver status is maintained, if
To take this option, inform the clerk of
court in the county where you received the citation that you
want to go to traffic school at the time that you pay the fine.
You cannot elect to go to traffic school after you pay the fine.
Then contact the traffic school of your choice to register. Traffic
schools are listed in your local telephone directory under "driving
instruction" or "traffic schools." Approved course
providers are also available online.
A full list of your options for satisfying your traffic citation
is on the back of the citation. You are required to choose one of
the three options within 30 days of receiving the citation.
Copyright ©2009
State of Florida


text:
Our society is slowly coming to grips with the magnitude of sexual harassment and sexual assault, not only in the civilian community but also in the armed forces. This devastating assault on the body and on the soul can't be healed by a self-help book or by toughing it out and going it alone. The depth of the pain and suffering of these wounds requires the skillful intervention of a counselor or therapist. If there are financial restrains, almost every community has some type of counseling service available to assist.
Likewise, the issue of post-traumatic stress disorder (PTSD) has long been ignored, but it is not an issue that we can wish away. This dreadful condition not only affects member of the armed forces, but it also has a profound ripple effect on family and community.
We can no longer hide from the depth of these pains. For those of you with the courage to share your stories, we salute you and applaud your courage.
These issues are so devastating and overwhelming that no human being can be expected to simply tough it out. We need help in dealing with these dreadful attacks on our dignity.
Edward T. Creagan, M.D.
Follow on Twitter:
Join the discussion at #Stress.
Original article: http://www.mayoclinic.org/healthy-living/stress-management/expert-blog/ptsd-assistance/bgp-20055956
Any use of this site constitutes your agreement to the Terms and Conditions and Privacy Policy linked below.
Mayo Clinic is a not-for-profit organization and proceeds from Web advertising help support our mission. Mayo Clinic does not endorse any of the third party products and services advertised.
A single copy of these materials may be reprinted for noncommercial personal use only. "Mayo," "Mayo Clinic," "MayoClinic.org," "Mayo Clinic Healthy Living," and the triple-shield Mayo Clinic logo are trademarks of Mayo Foundation for Medical Education and Research.


text:
For most of the details please check the first post in the thread.
I do have a couple new pieces of information I'd like to pass along.
1. The ramp system that they've worked on all summer at the Allisonville Road exit is open
2. In the past we've mainly pooled our money to pay the tab.
This time everyone will be taking care of their own check.
Pacer fans are always good at showing the waitress that takes care of us how much we appreciate their effort, let Saturday be no exception.
3. We have an area set aside for us on the right side of the floor. Its kind of walled off but not totally enclosed. I hope that makes more sence once you enter and see the layout. Try not to arrive too early. We have the space from 6:00 until whenever, so anytime after 5:45 should be ok. After 10:00 its an over 21 bar so I'd like to move over to Perkins between 10 and maybe 10:30'ish.
4. I warned Perkins that I was bringing in a large group Saturday night between 10 & 10:30. We even have our enclosed room that we like soooo much! For those new to the Castleton area, Perkins is located on the northeast corner of Allisonville Road and 82nd street. Everyone pays their own way at Perkins as well.
The poll shows we could have anywhere from 9 to 26. Either way, I'm really looking forward to Saturday night.
See ya there!


text:
Posted 5 years ago
(2 items)
Firstly, i would like to say, the larger image is of same medal/coin.
The smaller two are the coin i have in my hand, i couldnt enlarge the image so for ease i have displayed the other image, hopefully you may if interested enlarge my images of the said coin. i might add, if you do you will see it is of fine quality and in very good condition.
(deep intake of breath) I know it is circa 1748, showing the Duke of Cumberland striking Bonnie prince Charlie with a stick, cursing him "come back again" see what you get then.
As you probably know, it was made in support of the anti jacobites, at the battle of Culloden, in 1748, or there abouts.
I have searched the history if the peice but confused as to the value.
The value varies once again of between, £50 up to £300 ???? how can this be so?. Please if any one has a more concrete value, id be very appreciative,
thankyou and thankyou again in anticipation. Norma


text:
110 Tamarac Rd Northern Bruce Peninsula, ON N0H 2M0
Hi, RE/MAX Crossroads Realty Inc..
My name is
and I have a question about 110 Tamarac Rd Northern Bruce Peninsula
You can respond by either emailing me at
or call during
My Question Is:
Estimated Monthly Payment$5,051
- Photos
- Location
- Questions
- Share
- Mortgage Calculator
- Status: Active
Listing courtesy of ROYAL LEPAGE ESTATE REALTY, BROKERAGE - DONNA HARB, Salesperson
Waterfront Building Lot In Protected Lake Huron Bay! Just Over An Acre, Slightly Elevated & Treed Building Lot With Views Of Stokes Bay. This Is One Of Seven Lots That Have Been Severed With Deeded Ownership To Waterfront Across The Road With Approx 350Ft Of Shoreline. Dock, Driveway & Boat Launch Has Been Installed. Building Envelopes & Survey Available. Perfect Development Opportunity To Purchase One Or All!, This Lot Has An Existing Septic System And Drilled Well. Please Attach Schedule B For All Offers., Cross Street Stokes River Rd & Tamarac
Interior Features Include:No Information Available.
Exterior Features Include:
Acreage: 0.0000 Acres
Irregularities Irreg
Frontage 100.13
Depth 473.09
Other Features Include:
Water: None
Sewer: None
Sale/Lease Sale
Property Type Designated
Utilities A
Could not get neighborhood data.
RE/MAX Crossroads Realty Inc., Brokerage
Work: (416) 491-4002
Fax: (416) 756-1267
Email: email@example.com
Information provided by Toronto Real Estate Board, and is deemed reliable but not guaranteed accurate.


text:
How to identify high-value projects
Industry experts recommend a number of strategies to help users identify the most high-value applications and are nearly unanimous that the greatest ROI lies in the ability to continuously monitor field instruments.
The technology? HART. For years, instrument and systems vendors have been incorporating HART communications capabilities into field devices, enabling those devices to send digital information, including diagnostic information and secondary variables, to host systems. (The HART Communications Foundation estimates that more than 15 million HART-capable devices are installed worldwide.) But with the exception of maintenance personnel tramping into the field with handheld communicators to configure instruments, most users have left HARTs benefits untapped.
Those days are coming to an end, however. Instrument vendors are providing open access to their devices through readily available device descriptions; control systems providers are including HART I/O hardware in their products as well as asset management software; and many vendors are marketing products that enable the owners of legacy, analog-only systems to access the power of HART.
So, with HART data more accessible and potentially useful, key questions users face are:
- Whats the best way for my company to access that data?
- How do we identify applications in which we can use HART to generate business value?
A Brief History
HART, an acronym for Highway Addressable Remote Transducer, was developed in the late 1980s and became publicly available in the early 1990s.
Unlike other recent field communications protocols, such as Foundation Fieldbus and Profibus, which are totally digital, HART is a hybrid analog/digital technology. An instruments primary variable is transmitted via the industry standard analog 4-20 mA signal, but up to four secondary variables and device diagnostic information can be digitally piggybacked on it. As a result of these digital communications capabilities, users have access to extensive data from their devices, including diagnostic information and -- in the case of some instruments -- multiple process variables (i.e., a pressure transmitter also might be capable of providing temperature data).
In 1993, the former HART Users Group formed the HART Communications Foundation (HCF), which assumed ownership of the protocol and responsibility for administering and maintaining it. As part of its mission, HCF tests systems and devices for HART compliance and provides educational services to vendors and users.
In HARTs early years, many instrument vendors quickly adopted the technology, but kept a proprietary hold on the device descriptions that enable a host--such as a control system, an asset management system or a configurator--to communicate with its devices. Sandro Esposito, a Masoneilan digital products specialist, recalls that nearly every instrument maker had its own software package for talking to its device, effectively rendering that device an island of automation.
Charlie Piper, fieldbus product manager for Invensys Foxboro business unit, agreed. There are more than 500 different HART devices in the marketplace, and theres lots of information you can get about their performance, such as when valve positioners are starting to wear out or stick, he says. But until recently no one had come up with a way for all the host vendors to have a user interface to do these neat things with everyone else's device.
Today, however, most vendors make their Device Description (DD) files openly available. HCF maintains and distributes a library of hundreds of DDs that enable any HART host (e.g., control system, configurator, asset management system, safety system, etc.) to communicate with a vast array of field devices. That development is coupled with the development of comprehensive applications to monitor assets, such as Siemens Process Device Manager, Emerson Process Managements AMS Device Manager, and Honeywells Asset Manager PKS. As a result, users now are able to access most if not all of their device information from a single screen, regardless of device manufacturer.
In recent months, HCF has developed new tools and technologies to make development of HART-complaint DDs easier. These include the new Device Description Integrated Development Environment (DD-IDE), which is designed to streamline development, testing and maintenance of DDs and facilitate the creation of product applications with DD capabilities.
The DD-IDE supports the iterative DD development style with a fast and efficient integrated tool set. Each step in the edit-build-test cycle is supported in a DD-aware editing environment, says Wally Pratt, HCFs chief engineer.
Also near completion is the Enhanced Device Description Language (eDDLEDDL) specification. eDDLEDDL gives vendors the ability to add new capabilities to DDs while improving cross-platform compatibility and facilitating device set-up. (See details elsewhere in this supplement.)
HART-enabled instruments deliver greater value than ever before, says Dave Smith, manager of Yokogawas plant network technology center. The processing power of the devices is increasing greatly, says Smith. Therefore, field instruments feature additional functionality, including diagnostic type functions, predictive functions and others.
Jim Cobb, marketing manager of Emerson Process Managements Rosemount Division, notes that users are increasingly aware of the capabilities of the digital field. One of the reasons is that suppliers are better implementing features to use the capabilities of HART devices, says Cobb. Another reason, ironically, is that theres been so much talk about fieldbus in recent years. People are realizing that HART is capable of delivering many of the same benefits as fieldbus.
Identifying High-Value Applications
Industry experts are nearly unanimous that the greatest return on HART technology investment lies in the ability to continuously monitor the field instruments. Masoneilans Esposito notes that drastic reductions in maintenance staffs during the past decade have made automated monitoring of field instruments an absolute necessity in many plants. By being able to watch and track the condition of plant floor devices, maintenance and operations personnel can spot problems in the making and take action before they cause process upsets and unplanned shutdowns. Conversely, being able to see that a device is working well enables users to avoid unnecessary maintenance activities.
"If you have a lot of HART devices in your installation, and you're not monitoring them on a continuous basis, you're missing a great deal of opportunity, says Tom Holmes, president of MACTek, a manufacturer of HART modems. There's diagnostic information, alarms, alerts and confirmations of whether the analog signal is good or bad."
Industry experts recommended a number of strategies to help users identify the most high-value applications involving continuous monitoring.
Emersons Cobb suggests that plants go about taking advantage of HART gradually.
One of the nice things about HART is that you can add its capabilities to your plant, loop by loop, and gradually take your facility from analog to a fully integrated HART plant, says Cobb.
Id start with online monitoring of my most critical assets. Thats where Im going to get the most value from predictive diagnostics, such as being able to avoid unplanned shutdowns and preventing off-quality products, adds Cobb. At the same time, I might start using HART to monitor other instruments offline and gradually, as my maintenance budget allows, bring other assets online.
Marcelo Dultra, vice president of sales and marketing for Smar International, recommends plant audits as a means of identifying areas ripe for improvement via HART. They should do a full check of what equipment they have installed and what technologies theyre using. This kind of thing usually takes a maximum of two or three days, says Dultra, who adds that Smar, as well as other vendors and consulting firms, provide such services.
"It's always good to get opinions from outside the plant, from people who have seen other operations. If you work a long period in your own plant, you miss some points that are important, especially when it comes to the technologies available today, he adds.
Prasad Raghavendra, Honeywells product manager for all systems-related HART products, recommends that users review a history of process upsets and their causes to identify areas that are ripe for HART-enabled continuous monitoring. Make a business plan out of that to determine if the cost of incidents are higher than the cost for investing in HART-enabled I/O, says Raghavendra. Thats a fairly simple method that would clearly indicate whether it was worth it for the customer to make the investment.
In some instances, he says, the benefits from investing in HART will be plain. For example, your plant could be having problems caused by simple incidents like sensor failures. If youre simply relying on a 4-20 mA signal, the operator will see a local trip, but everything in that group of devices becomes suspect. This requires the operator calling maintenance and what could be an extensive debugging process. With HART, however, if theres a sensor failure, the device tells you that its the source of the problem, saving you time and resources in correcting the malfunction.
Processes that could benefit the most from this technology are those with a large number of remote-connected HART devices that can be brought in to a control system through remote HART I/O, says Eric Olson, a senior product manager with ABB. This could include processes such as those in the oil and gas or wastewater treatment industries, where there are many satellite I/O stations.
Foxboros Piper recommends that users employ a diagnostic tool such as ExperTunes PlantTriage, to monitor loops and field instrument performance and identify potential troublespots that could benefit from full time monitoring via HART.
HART can play an important role in refineries, mills and power plants that employ process safety systems. To maintain a systems Safety Integrity Level (SIL) rating, safety system valves must be periodically tested to ensure that they will move if called upon in an emergency. Full-range tests can be conducted only during plant shutdowns, but these occur only every two to three years. However, by stroking a valve by as little as 10 percent, which does not disrupt a process, plants can ensure the reliability of their safety valves. A valve positioner has the ability, via HART, to confirm to operators that the valve actually responded to the movement command.
Robert Hotard, a product manager with instrument-maker K-Tek, also suggests that users take advantage of HCFs expertise in planning HART-based projects. The first thing Id recommend to anyone interested in HART is to go to the HART Communication Foundations website, says Hotard. Theres a lot of information there thats available to everyone and explains in great detail how to use the protocol and the benefits that are possible. Im currently writing some manuals for K-Tek products, and in them I specifically reference the HCF website.
Dont Overlook Control Opportunities
While most facilities use HART for applications related to device configuration and maintenance, users also should look for opportunities to use HART data for process monitoring as well. For example, in applications where conditions such as temperature, pressure and levels change relatively slowly, users can reduce the number of instruments they need in the field by acquiring multiple variables from a single device. Hotard points to tank farms as being ideal sites in which to make use of HART for applications such as inventory monitoring.
In relatively small operations, users can set up set up modest, but effective SCADA systems that utilize HART technology, says Macteks Holmes. You could continuously monitor up to eight points using a PC equipped with eight USB HART modems. Thats very do-able, says Holmes. For software, you could use a dedicated data acquisition package such as Wonderwares InTouch software, or something as basic as a Microsoft Excel spreadsheet. I think there are plenty of operations such as bakeries or small specialty chemical plants that cant justify spending the money for a large control system. But with HART input and a PC, you can build yourself a quick and dirty DCS, he adds.
Liberate the Genie
Having HART capabilities at your disposal, but not taking advantage of them, is like keeping the genie stuffed in the lamp. By carefully examining your facility, looking at the HART capabilities you already have, and carefully weighing the need for additional investments, you can take full advantage of opportunities for improvement.
Keys to HART Value
- Identify the most critical loops in your plant first and begin monitoring them via HART on a full-time basis. Other less essential loops can be monitored offline periodically.
- An outsider can bring fresh perspective. So consider bringing in an outside consultant to help you identify areas where you can realize maximum benefit from HART-based solutions.
- Make a business plan out of that to determine if the cost of incidents are is higher than the cost for of investing in HART-enabled I/O.
- Employ a diagnostic tool to monitor loops and field instrument performance and identify potential troublespots that could benefit from full time monitoring via HART.
- Take advantage of resources and training provided by HART Communications Foundation.
- While HART is used primarily for equipment monitoring and configuration purposes, dont overlook opportunities to use it in appropriate control applications.
Join the discussion
We welcome your thoughtful comments.
All comments will display your user name.
Want to participate in the discussion?Register for free
Log in for complete access.
No one has commented on this page yet.
RSS feed for comments on this page | RSS feed for all comments